Targeting the p53 tumor suppressor gene function in glioblastomas using small chemical molecules

Drug Development Research

Volumn 67, Issue 10, 2006, Pages 790-800

  Magrini, Roberta ^a   Bakker, Annette ^a   Gaviraghi, Giovanni ^a   Terstappen, Georg C ^a  

^a Siena Biotech SpA   (Italy)

Author keywords

Glioblastoma; hdm2; Nutlins; p53; PRIMA 1

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; 4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; 7 NITRO 5 DEAZAFLAVIN; 9 HYDROXYELLIPTICINE; ANTISENSE OLIGONUCLEOTIDE; BENZODIAZEPINE DERIVATIVE; CHALCONE DERIVATIVE; CHLOROFUSIN; FURAN DERIVATIVE; HLI 98 C; IMIDAZOLINE DERIVATIVE; MALEIMIDE DERIVATIVE; MIRA 1; NORBORNANE DERIVATIVE; NUTLIN 3; PRIMA 1; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; QUERCETIN DERIVATIVE; QUINUCLIDIONE; TDP 665759; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; CELL CYCLE ARREST; CELL SURVIVAL; DNA BINDING; DNA REPAIR; DRUG STRUCTURE; GENE FUNCTION; GENE MUTATION; GENE TARGETING; GLIOBLASTOMA; HUMAN; IONIZING RADIATION; PROTEIN PROTEIN INTERACTION; REVIEW; TUMOR SUPPRESSOR GENE; WILD TYPE;

EID: 33846409035     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20151     Document Type: Review

References (102)

1. Amundson SA, Patterson A, Do KT, Fornace AJ Jr. 2002. A nucleotide excision repair master-switch: p53 regulated coordinate induction of global genomic repair genes. Cancer Biol Ther 1: 145-149.
2. Bensaad K, Tsuzuta A, Selak MA, Vidal MN, Nakano K, Bartoris K, Gottlieb E, Vousden KH. 2006. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126:107-120.
3. Bogler O, Mikkelsen T. 2005. Angiogenesis and apoptosis in glioma: two arenas for promising new therapies. J Cell Biochem 96:16-24.
4. Bykov VJ, Issaeva N, Selivanova G, Wiman KG. 2002. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 23: 2011-2018.
5. Bykov VJ, Selivanova G, Wiman KG. 2003. Small molecules that reactivate mutant p53. Eur J Cancer 39:1828-1834.
6. Bykov VJ, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J, Selivanova G, Wiman KG. 2005. Reactivation of mutant p.53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 280:30384-30391.
7. Carpentier AF. 2005. Neuro-oncology: the growing role of chemotherapy in glioma. Lancet Neurol 4:4-5.
8. Chen J, Wu X, Lin J, Levine AJ. 1996. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 16:2445-2452.
9. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP. 2005. Crucial role of p53-dependent cellular senescence in suppression ol Pten-deficient tumorigenesis. Nature 436:725-730.
10. Chene P. 2004. Inhibition of the p.53-MDM2 interaction: targeting a protein-protein interface. Mol Cancer Res 2:20-28.
11. Chipuk JE, Green DR. 2006. Dissecting p.53-dependent apoptosis. Cell Death Diff 13:994-1002.
12. Cirielli C, Inyaku K, Capogrossi MC, Yuan X, Williams JA. 1999. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma. J Neurooncol 43:99-108.
13. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, Cosialls AM, de Frias M, Castano E, Campas C, Barragan M, de Sevilla AF, Domingo A, Vassilev LT, Pons G, Gil J. 2006. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 107:4109-4114.
14. Datta K, Shah P, Srivastava T, Mathur SG, Chattopadhyay P, Sinha S. 2004. Sensitizing glioma cells to cisplatin by abrogating the p53 response with antisense oligonucleotides. Cancer Gene Ther 11: 525-531.
15. Demma MJ, Wong S, Maxwell E, Dasmahapatra B. 2004. CP-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73. J Biol Chem 279:45887-45896.
16. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. 1995. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1checkpoint control. Cell 82:675-684.
17. Dimri GP. 2005. What has senescence got to do with cancer? Cancer Cell 7:505-512.
18. Duncan SJ, Gruschow S, Williams DH, McNicholas C, Purewal R, Hajek M, Gerlitz M, Martin S, Wrigley SK, Moore M. 2001. Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J Am Chem Soc 123:554-560.
19. El-Deiry WS. 2003. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22:7486-7495.
20. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. 1993. WAF1, a potential mediator of p-53 tumor suppression. Cell 75:817-825.
21. Erster S, Mihara M, Kim RH, Petrenko O, Moll UM. 2004. In vivo mitochondrial p.53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol 24:6728-6741.
22. Evan G, Littlewood T. 1998. A matter of life and cell death. Science 281:1317-1322.
23. Fischer PM, Lane DP. 2004. Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets? Trends Pharmacol Sci 25:343-346.
24. Foster BA, Coffey HA, Morin MJ, Rastinejad F. 1999. Pharmacological rescue of mutant p53 conformation and function. Science 286:2507-2510.
25. Freedman DA, Wu L, Levine AJ. 1999. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 55:96-107.
26. Fridman JS, Lowe SW. 2003. Control of apoptosis by p53. Oncogene 22:9030-9040.
27. Friedler A, Hansson LO, Veprintsev DB, Freund SM, Rippin TM, Nikolova PV, Proctor MR, Rudiger S, Fersht AR. 2002. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA 99: 937-942.
28. Fulci G, Labuhn M, Maier D, Lachat Y, Hausmann O, Hegi ME, Janzer RC, Merlo A, Van Meir EG. 2000. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 19:3816-3822.
29. Garcia-Echeverria C, Chene P, Blommers MJ, Furet P. 2000. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. J Med Chem 43: 3205-3208.
30. Gatz SA, Wiesmuller L. 2006. p53 in recombination and repair. Cell Death Differ 13:1003-1016.
31. Gilbertson RJ. 2006. High-grade glioma: can we teach an old dogma new tricks? Cancer Cell 9:147-148.
32. Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, Steck KD, Levin VA, Yung WK. 1996. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 56:694-699.
33. Hardcastle IR, Ahmed SU, Atkins H, Calvert AH, Curtin NJ, Farnie G, Golding BT, Griffin RJ, Guyenne S, Hutton C, Kallblad P, Kemp SJ, Kitching MS, Newell DR, Norbedo S, Northen JS, Reid RJ, Saravanan K, Willems HM, Lunec J. 2005. Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction. Bioorg Med Chem Lett 15:1515-1520.
34. Harris LC, Remack JS, Houghton PJ, Brent TP. 1996. Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene. Cancer Res 56:2029-2032.
35. Harris SL, Levine AJ. 2005. The p53 pathway: positive and negative feedback loops. Oncogene 24:2899-2908.
36. Haupt Y, Maya R, Kazaz A, Oren M. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
37. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. 2005. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003.
38. Hermisson M, Klumpp A, Wick W, Mischhusen J, Nagel G, Roos W, Kaina B, Weller M. 2006. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 96:766-776.
39. Honda R, Tanaka H, Yasuda H. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420: 25-27.
40. Houillier C, Lejeune J, Benouaich-Amiel A, Laigle-Donadey F, Criniere E, Mokhtari K, Thillet J, Delattre JY, Hoang-Xuan K, Sanson M. 2006. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 106:2218-2223.
41. Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A, Collins VP. 2000. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 60:417-424.
42. Issaeva N, Friedler A, Bozko P, Wiman KG, Fersht AR, Selivanova G. 2003. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc Natl Acad Sci USA 100: 13303-13307.
43. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G. 2004. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10:1321-1328.
44. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B. 1991. Identification of p53 as a sequence-specific DNA-binding protein. Science 252:1708-1711.
45. Klein C, Vassilev LT. 2004. Targeting the p53-MDM2 interaction to treat cancer. Br J Cancer 91:1415-1419.
46. Koblish HK, Zhao S, Franks CF, Donatelli RR, Tominovich RM, LaFrance LV, Leonard KA, Gushue JM, Parks DJ, Calvo RR, Milldewicz KL, Marugan JJ, Raboisson P, Cummings MD, Grasberger BL, Johnson DL, Lu T, Molloy CJ, Maroney AC. 2006. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol Cancer Ther 5:160-169.
47. Kubbutat MH, Jones SN, Vousden KH. 1997. Regulation of p53 stability by Mdm2. Nature 387:299-303.
48. Kumar SK, Hager E, Pettit C, Gurulingappa H, Davidson NE, Khan SR. 2003. Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. J Med Chem 46: 2813-2815.
49. Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S, Berger MS, McDermott MW, Kunwar SM, Junck LR, Chandler W, Zwiebel JA, Kaplan RS, Yung WK. 2003. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 21: 2508-2518.
50. Larsson O. 2005. Cellular senescence: an integrated perspective. Cancer Therapy 3:495-510.
51. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G, Hakem R, Benchimol S. 2003. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112: 779-971.
52. Louis DN. 1994. The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53:11-21.
53. Lowe SW, Sherr CJ. 2003. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 13:77-83.
54. Mann K, Hainaut P. 2005. Aminothiol WR1065 induces differential gene expression in the presence of wild-type p53. Oncogene 2: 3964-3975.
55. Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. 2002. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 277:5484-5489.
56. Meek DW, Knippschild U. 2003. Posttranslational modification of MDM2. Mol Cancer Res 1:1017-1026.
57. Michiue H, Tomizawa K, Matsushita M, Tamiya T, Lu YF, Ichikawa T, Date I, Matsui H. 2005. Ubiquitination-resistant p53 protein transduction therapy facilitates anti-cancer effect on the growth of human malignant glioma cells. FEBS Lett 579:3965-3969.
58. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Paneoska P Moll UM. 2003. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11:577-590.
59. North S, El-Ghissassi F, Pluqnet O, Verhaegh G, Hainaut P 2000. The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p.53-dependent pathway. Oncogene 19:1206-1214.
60. Okamoto K, Li H, Jensen MR, Zhang T, Taya Y, Thorgeirsson SS, Prives C. 2002. Cyclin G recruits PP2A to dephosphorylate Mdm2. Mol Cell 9:761-771.
61. Onel K, Cordon-Cardo C. 2004. MDM2 and prognosis. Mol Cancer Res 2:1-8.
62. Oren M. 1999. Regulation of the p53 tumor suppressor protein. J Biol Chem 274:36031-36034.
63. Pearson S, Jia H, Kandachi K. 2004. China approves first gene therapy. Nat Biotechnol 22:3-4.
64. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. 2006. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173.
65. Prasad G, Wang H, Agrawal S, Zhang R. 2002. Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme. Anticancer Res 22:107-116.
66. Rainov NG, Dobberstein KU, Bahn H, Holzhausen HJ, Lautenschlager C, Heidecke V, Burkert W. 1997. Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neurooncol 35:13-28.
67. Reardon DA, Wen PY. 2006. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 11:152-164.
68. Reifenberger G, Du L, Ichimura K, Schmidt EE, Collins VP 1993. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53:2736-2739.
69. Riemenschneider MJ, Buschges R, Wolter M, Reifenberger J, Bostrom J, Kraus JA, Schlegel U, Reifenberger G. 1999. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res 59: 6091-6096.
70. Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht AR. 2002. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 21:2119-2129.
71. Royds JA, Iacopetta B. 2006. p53 and disease: when the guardian angel fails. Cell Death Differ 13:1017-1026.
72. Schiebe M, Ohneseit P, Hoffmann W, Meyermann R, Rodemann HP, Bamberg M. 2000. Analysis of mdm2 and p.53 gene alterations in glioblastomas and its correlation with clinical factors. J Neurooncol 49:197-203.
73. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B, Wiestler OD, Louis DN, Fimmers R, von Deimling A. 2002. Impact of genotype and morphology on the prognosis of glioblastoma. J Neurophatol Exp Neurol 61:321-328.
74. Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Grauer B, Grafstrom RC, Wiman KG. 1997. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 3:632-638.
75. Soussy T. 2000. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann NY Acad Sci 910:121-137.
76. Smart P, Lane EB, Lane DP, Midgley C, Vojtesek B, Lain S. 1999. Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene 18:7378-7386.
77. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB. 2001. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246-1256.
78. Stoll R, Renner C, Hansen S, Palme S, Klein C, Belling A, Zeslawski W, Kamionka M, Rehm T, Muhlhaln P, Schumacher R, Hesse F, Kaluza B, Voelter W, Engh RA, Holak TA. 2001. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 40:336-344.
79. Sngikawa E, Hosoi T, Yazaki N, Gamanuma M, Nakanishi N, Ohashi M. 1999. Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. Anticancer Res 19: 3099-3108.
80. Takenobu T, Tomizawa K, Matsushita M, Li ST, Moriwaki A, Lu YF, Matsui H. 2002. Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol Cancer Ther 1:1043-1049.
81. Takimoto R, MacLachlan TK, Dicker DT, Niitsu Y, Mori T, El-Deiry WS. 2002a. BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation. Cancer Biol Ther 1:177-186.
82. Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, El-Deiry WS. 2002b. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 1: 47-55.
83. Tan T, Chu G. 2002. p.53 Binds and activates the xeroderma pigmentosum DDB2 gene in humans but not mice. Mol Cell Biol 22: 3247-3254.
84. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, Nakamura Y. 2000. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404:42-49.
85. Taylor WR, Stark GR. 2001. Regulation of the G2/M transition by p53. Oncogene 20:1803-1815.
86. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC, Vassilev LT 2006. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 103:1888-1893.
87. Ushio Y, Tada K, Shiraishi S, Kamiryo T, Shinojima N, Kochi M, Saya H. 2003. Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma. Front Biosci 8: e281-e288.
88. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848.
89. Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408:307-310.
90. von Deimling A, Louis DN, Menon AG, von Ammon K, Petersen I, Ellison D, Wiestler OD, Seizinger BR. 1993. Deletions on the long arm of chromosome 17 in pilocytic astrocytoina. Acta Neuropathol (Berl) 86:81-85.
91. Wang H, Zeng X, Oliver P, Le LP, Chen J, Chen L, Zhou W, Agrawal S, Zhang R. 1999. MDM2 oncogene as a target for cancer therapy: an antisense approach. Int J Oncol 15:653-660.
92. Wang H, Oliver P, Zhang Z, Agrawal S, Zhang R. 2003. Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms. Ann N Y Acad Sci 1002:217-235.
93. Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M. 2003. CP-31398, a novel p53-stabilizing agent, induces p53-depedent and p53-independent glioma cell death. Oncogene 22: 8233-8245.
94. Wu X, Bayle JH, Olson D, Levine AJ. 1993. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7:1126-1132.
95. Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV, Safiran YJ, Oberoi P, Renten JH, Phillips AC, Weissman AM, Vousden KH. 2005. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7: 547-559.
96. Yee KS, Vousden KH. 2005. Complicating the complexity of p53. Carcinogenesis 26:1317-1322.
97. Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R. 2004a. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem. 279:16000-16006.
98. Zhang Z, Wang H, Prasad G, Li M, Yu D, Bonner JA, Agrawal S, Zhang R. 2004b. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res 10:1263-1273.
99. Zhang Z, Wang H, Li M, Rayburn E, Agrawal S, Zhang R. 2005. Novel MDM2 p53-independent functions identified through RNA silencing technologies. Ann NY Acad Sci 1058:205-214.
100. Zhao J, Wang M, Chen J, Luo A, Wang X, Wu M, Yin D, Liu Z. 2002. The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. Cancer Lett 183:69-77.
101. Zhou BP, Hung MC. 2002. Novel targets of Akt, p21(Cip1/WAF1), and MDM2. Semin Oncol 29:62-70.
102. Zou Z, Gao C, Nagaich AK, Connell T, Saito S, Moul JW, Seth P, Appella E, Srivastava S. 2000. p53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem 275: 6051-6054.